|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vargas AN: Natural history of ovarian
cancer. Ecancermedicalscience. 8:4652014.PubMed/NCBI
|
|
3
|
Tomao F, Papa A, Rossi L, Strudel M, Vici
P, Lo Russo G and Tomao S: Emerging role of cancer stem cells in
the biology and treatment of ovarian cancer: Basic knowledge and
therapeutic possibilities for an innovative approach. J Exp Clin
Cancer Res. 32:482013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bhattacharya R, Nicoloso M, Arvizo R, Wang
E, Cortez A, Rossi S, Calin GA and Mukherjee P: MiR-15a and MiR-16
control Bmi-1 expression in ovarian cancer. Cancer Res.
69:9090–9095. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Edwards BK, Brown ML, Wingo PA, Howe HL,
Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, et al:
Annual Report to the nation on the status of cancer, 1975–2002,
featuring population-based trends in cancer treatment. J Natl
Cancer Inst. 97:1407–1427. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu HY, Wang Y, Zhang H, et al: The long
non-coding RNA UCA1, as a prognostic biomarker for high grade
serous ovarian carcinoma. Eur J Gynaecological Oncol. 38:883–889.
2017.
|
|
7
|
Chekerov R, Braicu I, Castillo-Tong DC,
Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T,
Speiser P, et al: Outcome and clinical management of 275 patients
with advanced ovarian cancer international federation of obstetrics
and Gynecology II to IV inside the european ovarian cancer
translational research consortium-OVCAD. Int J Gynecol Cancer.
23:268–275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peiretti M, Bristow RE, Zapardiel I,
Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD
and Maggioni A: Rectosigmoid resection at the time of primary
cytoreduction for advanced ovarian cancer. A multi-center analysis
of surgical and oncological outcomes. Gyneco l. Oncol. 126:220–223.
2012.
|
|
9
|
Chen CY, Chang HP, Ng KK, Wang CC, Lai CH
and Chao A: Long-term disease-free survival in three ovarian cancer
patients with a single relapse. Eur J Gynaecol Oncol.
33:3212012.PubMed/NCBI
|
|
10
|
Yuan B, Liang Y, Wang D and Luo F: MiR-940
inhibits hepatocellular carcinoma growth and correlates with
prognosis of hepatocellular carcinoma patients. Cancer Sci.
106:819–824. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chou CK, Chen RF, Chou FF, Chang HW, Chen
YJ, Lee YF, Yang KD, Cheng JT, Huang CC and Liu RT: miR-146b is
highly expressed in adult papillary thyroid carcinomas with high
risk features including extrathyroidal invasion and the BRAF(V600E)
mutation. Thyroid. 20:489–494. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu N, Papagiannakopoulos T, Pan G, Thomson
JA and Kosik KS: MicroRNA-145 regulates OCT4, SOX2, and KLF4 and
represses pluripotency in human embryonic stem cells. Cell.
137:647–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuehbacher A, Urbich C, Zeiher AM and
Dimmeler S: Role of Dicer and Drosha for endothelial microRNA
expression and angiogenesis. Circ Res. 101:59–68. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Würdinger T, Tannous BA, Saydam O, Skog J,
Grau S, Soutschek J, Weissleder R, Breakefield XO and Krichevsky
AM: miR-296 regulates growth factor receptor overexpression in
angiogenic endothelial cells. Cancer Cell. 14:382–393. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun
S, Hong L, Liu J and Fan D: miR-15b and miR-16 modulate multidrug
resistance by targeting BCL2 in human gastric cancer cells. Int J
Cancer. 123:372–379. 2010. View Article : Google Scholar
|
|
16
|
Mitamura T, Watari H, Wang L, Kanno H,
Hassan MK, Miyazaki M, Katoh Y, Kimura T, Tanino M, Nishihara H, et
al: Downregulation of miRNA-31 induces taxane resistance in ovarian
cancer cells through increase of receptor tyrosine kinase MET.
Oncogenesis. 2:e402013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aqeilan RI, Calin GA and Croce CM: miR-15a
and miR-16-1 in cancer: Discovery, function and future
perspectives. Cell Death Differentiation. 17:2152010. View Article : Google Scholar
|
|
18
|
Chung YW, Bae HS, Song JY, Lee JK, Lee NW,
Kim T and Lee KW: Detection of microRNA as novel biomarkers of
epithelial ovarian cancer from the serum of ovarian cancer
patients. Int J Gynecol Cancer. 23:673–679. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shapira I, Oswald M, Lovecchio J, Khalili
H, Menzin A, Whyte J, Dos Santos L, Liang S, Bhuiya T, Keogh M, et
al: Circulating biomarkers for detection of ovarian cancer and
predicting cancer outcomes. Br J Cancer. 110:976–983. 2014.
View Article : Google Scholar :
|
|
20
|
Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W,
Chang G, Li X, Li Q, Wang S and Wang W: MicroRNA profiling implies
new markers of chemoresistance of triple-negative breast cancer.
PLoS One. 9:e962282014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mihelich BL, Khramtsova EA, Arva N,
Vaishnav A, Johnson DN, Giangreco AA, Martens-Uzunova E, Bagasra O,
Kajdacsy-Balla A and Nonn L: miR-183-96-182 cluster is
overexpressed in prostate tissue and regulates zinc homeostasis in
prostate cells. J Biol Chem. 286:44503–44511. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lumayag S, Haldin CE, Corbett NJ, Wahlin
KJ, Cowan C, Turturro S, Larsen PE, Kovacs B, Witmer PD, Valle D,
et al: Inactivation of the microRNA-183/96/182 cluster results in
syndromic retinal degeneration. Proc Natl Acad Sci USA.
110:E507–E516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kundu ST, Byers LA, Peng DH, Roybal JD,
Diao L, Wang J, Tong P, Creighton CJ and Gibbons DL: The miR-200
family and the miR-183~96~182 cluster target Foxf2 to inhibit
invasion and metastasis in lung cancers. Oncogene. 35:173–186.
2016. View Article : Google Scholar
|
|
24
|
Lan HY: Diverse Roles of TGF-β/Smads in
Renal Fibrosis and Inflammation. Int J Biol Sci. 7:1056–1067. 2011.
View Article : Google Scholar :
|
|
25
|
Massagué J: TGFbeta in Cancer. Cell.
134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Biankin AV, Morey AL, Lee CS, Kench JG,
Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL and Henshall
SM: DPC4/Smad4 expression and outcome in pancreatic ductal
adenocarcinoma. J Clin Oncol. 20:4531–4542. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang
J, Perry SR, Labrot ES, Wu X, Lis R, et al: SMAD4-dependent barrier
constrains prostate cancer growth and metastatic progression.
Nature. 470:269–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alazzouzi H, Alhopuro P, Salovaara R,
Sammalkorpi H, Järvinen H, Mecklin JP, Hemminki A, Schwartz S Jr,
Aaltonen LA and Arango D: SMAD4 as a prognostic marker in
colorectal cancer. Clin Cancer Res. 11:2606–2611. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Geraldo MV, Yamashita AS and Kimura ET:
MicroRNA miR-146b-5p regulates signal transduction of TGF-β by
repressing SMAD4 in thyroid cancer. Oncogene. 31:1910–1922. 2012.
View Article : Google Scholar
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using realtime quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:4024082001. View Article : Google Scholar
|
|
31
|
Tsai MM, Wang CS, Tsai CY, Huang HW, Chi
HC, Lin YH, Lu PH and Lin KH: Potential diagnostic, prognostic and
therapeutic targets of MicroRNAs in human gastric cancer. Int J Mol
Sci. 17:pii: E9452016. View Article : Google Scholar
|
|
32
|
Kasinski AL and Slack FJ: MicroRNAs en
route to the clinic: Progress in validating and targeting microRNAs
for cancer therapy. Nat Rev Cancer. 11:849–864. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li C, Deng L, Zhi Q, Qian A, Sang H, Li X
and Xia J: MicroRNA-183 functions as an oncogene by regulating
PDCD4 in gastric cancer. Anticancer Agents Med Chem. 16:447–455.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gu W, Gao T, Shen J, Sun Y, Zheng X, Wang
J, Ma J, Hu XY, Li J and Hu MJ: MicroRNA-183 inhibits apoptosis and
promotes proliferation and invasion of gastric cancer cells by
targeting PDCD4. Int J Clin Exp Med. 7:2519–2529. 2014.PubMed/NCBI
|
|
35
|
Bi DP, Yin CH, Zhang XY, Yang NN and Xu
JY: MiR-183 functions as an oncogene by targeting ABCA1 in colon
cancer. Oncol Rep. 35:2873–2879. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ren LH, Chen WX, Li S, He XY, Zhang ZM, Li
M, Cao RS, Hao B, Zhang HJ, Qiu HQ and Shi RH: MicroRNA-183
promotes proliferation and invasion in oesophageal squamous cell
carcinoma by targeting programmed cell death 4. Br J Cancer.
111:2003–2013. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Torbenson M, Marinopoulos S, Dang DT,
Choti M, Ashfaq R, Maitra A, Boitnott J and Wilentz RE: Smad4
overexpression in hepatocellular carcinoma is strongly associated
with transforming growth factor beta II receptor immunolabeling.
Hum Pathol. 33:871–876. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee DK, Park SH, Yi Y, Choi SG, Lee C,
Parks WT, Cho H, de Caestecker MP, Shaul Y, Roberts AB and Kim SJ:
The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta
family signaling through direct interaction with Smad4: Potential
mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev.
15:455–466. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao W, Yang H, Li J, Chen Y, Cao J, Zhong
T, Wang L, Guo J, Li L and Zhang H: MiR-183 promotes preadipocyte
differentiation by suppressing Smad4 in goats. Gene. 666:158–164.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ang CW, Nedjadi T, Sheikh AA, Tweedle EM,
Tonack S, Honap S, Jenkins RE, Park BK, Schwarte-Waldhoff I,
Khattak I, et al: Smad4 loss is associated with fewer
S100A8-positive mono-cytes in colorectal tumors and attenuated
response to S100A8 in colorectal and pancreati. cancer cells
Carcinogenesis. 31:1541–1551. 2010. View Article : Google Scholar
|
|
41
|
Argani P, Shaukat A, Kaushal M, Wilentz
RE, Su GH, Sohn TA, Yeo CJ, Cameron JL, Kern SE and Hruban RH:
Differing rates of loss of DPC4 expression and of p53
overexpression among carcinomas of the proximal and distal bile
ducts. Cancer. 91:1332–1341. 2015. View Article : Google Scholar
|
|
42
|
Torbenson M, Marinopoulos S, Dang DT,
Choti M, Ashfaq R, Maitra A, Boitnott J and Wilentz RE: Smad4
overexpression in hepatocellular carcinoma is strongly associated
with transforming growth factor beta II receptor immunolabeling.
Human Pathol. 33:871–876. 2002. View Article : Google Scholar
|
|
43
|
Ouyang L, Liu P, Yang S, Ye S, Xu W and
Liu X: A three-plasma miRNA signature serves as novel biomarkers
for osteosarcoma. Med Oncol. 30:3402013. View Article : Google Scholar
|
|
44
|
Novello C, Pazzaglia L, Cingolani C, Conti
A, Quattrini I, Manara MC, Tognon M, Picci P and Benassi MS: MiRNA
expression profile in human osteosarcoma: Role of miR-1 and
miR-133b in proliferation and cell cycle control. Int J Oncol.
42:667–675. 2013. View Article : Google Scholar
|
|
45
|
Maire G, Martin JW, Yoshimoto M,
Chilton-MacNeill S, Zielenska M and Squire JA: Analysis of
miRNA-gene expression-genomic profiles reveals complex mechanisms
of microRNA deregulation in osteosarcoma. Cancer Genet.
204:138–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xue J, Lin X, Chiu WT, Chen YH, Yu G, Liu
M, Feng XH, Sawaya R, Medema RH, Hung MC and Huang S: Sustained
activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer
metastasis. J Clin Invest. 124:564–579. 2014. View Article : Google Scholar : PubMed/NCBI
|
